Table 5 Clinical remission at week 17 ± 0.5: univariable analysis of baseline parameters in patients with CD
CD patients with clinical remission | CD patients with no clinical remission | p-value | ||
|---|---|---|---|---|
Disease duration from initial diagnosis (years) | 11.8 ± 1.9 | 13.4 ± 1.3 | 0.42 | M |
Age at initial diagnosis (years) | 28.8 ± 2.8 | 23.4 ± 1.5 | 0.09 | M |
CRP (mg/L) | 7.0 ± 1.4 | 13.5 ± 3.1 | 0.43 | M |
Hb (g/dL) | 13.5 ± 0.4 | 12.6 ± 0.3 | 0.05 | U |
Leukocytes × 103/µL | 8.9 ± 0.7 | 10.4 ± 0.7 | 0.16 | M |
Endoscopic disease activity | 14.4 ± 1.4 | 12.9 ± 1.5 | 0.58 | U |
Clinical disease activity (HBI) | 5.9 ± 0.8 | 9.4 ± 0.8 | 0.002 | M |
Disease extent (L1/L2/L3)/n (%) | (3/5/18)/26 (12/19/69) | (11/5/31)/47 (23/11/66) | 0.34 | C |
First flare treated with corticosteroids (%) | 18/24 (75) | 43/47 (92) | 0.08 | F |
Previous treatment with anti TNF-α antibody (%) | 20/26 (77) | 46/47 (98) | 0.007 | F |
Active smoking (%) | 5/26 (19) | 15/47 (32) | 0.29 | F |
Concomitant corticosteroid therapy (%) | 12/26 (46) | 28/44 (64) | 0.21 | F |
Prior bowel surgery (%) | 7/26 (27) | 15/47 (32) | 0.79 | F |
Phenotype (B1/B2/B3)/n (%) | (7/11/8)/26 (27/42/31) | (11/18/18)/47 (24/38/38) | 0.81 | C |
Extraintestinal manifestations (%) | 7/26 (27) | 18/49 (37) | 0.45 | F |